“Eli Lilly and Company (NYSE: LLY) and Incyte (N
Post# of 148282
NP once mentioned long ago that there was an offer to combine leronlimab with remdesevir in a trial. Personally, at the time and now, I was for a combined trial because the other entity (NIH, BP, hospital, etc.) would help with funding and the trial would’ve likely been enrolled quicker.
Let’s get these S/C trial results out and compete with these other companies.